Shares of Juno Therapeutics Inc (NASDAQ:JUNO) saw strong trading volume on Friday . 12,479,353 shares were traded during mid-day trading, an increase of 475% from the previous session’s volume of 2,170,435 shares.The stock last traded at $27.98 and had previously closed at $40.82.

A number of analysts recently commented on the company. FBR & Co reaffirmed a “buy” rating and issued a $73.00 target price on shares of Juno Therapeutics in a research report on Saturday, April 9th. Cowen and Company assumed coverage on Juno Therapeutics in a research note on Thursday, May 5th. They set an “outperform” rating and a $55.00 price target for the company. Vetr upgraded Juno Therapeutics from a “buy” rating to a “strong-buy” rating and set a $54.66 price target for the company in a research note on Wednesday, June 8th. Leerink Swann reiterated an “outperform” rating and set a $67.00 price target on shares of Juno Therapeutics in a research note on Friday, March 18th. Finally, Zacks Investment Research downgraded Juno Therapeutics from a “buy” rating to a “hold” rating in a research note on Monday, April 25th. Four research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the stock. The company presently has a consensus rating of “Buy” and an average price target of $53.11.

The firm has a 50 day moving average price of $41.76 and a 200-day moving average price of $38.56. The firm’s market cap is $2.81 billion.

Juno Therapeutics (NASDAQ:JUNO) last released its quarterly earnings data on Monday, May 9th. The biopharmaceutical company reported ($0.78) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.52) by $0.26. The firm had revenue of $9.80 million for the quarter, compared to analysts’ expectations of $4.83 million. During the same quarter in the prior year, the firm earned ($0.30) EPS. Analysts anticipate that Juno Therapeutics Inc will post ($2.09) earnings per share for the current year.

In other news, CEO Hans Edgar Bishop sold 90,750 shares of the stock in a transaction on Thursday, June 9th. The shares were sold at an average price of $46.42, for a total value of $4,212,615.00. Following the sale, the chief executive officer now owns 2,704,609 shares in the company, valued at $125,547,949.78. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Steve Harr sold 30,000 shares of the stock in a transaction on Friday, June 10th. The stock was sold at an average price of $43.32, for a total transaction of $1,299,600.00. Following the completion of the sale, the chief financial officer now owns 716,052 shares in the company, valued at approximately $31,019,372.64. The disclosure for this sale can be found here.

Other hedge funds have recently made changes to their positions in the company. Baillie Gifford & Co. purchased a new stake in shares of Juno Therapeutics during the fourth quarter worth about $12,312,000. California Public Employees Retirement System increased its stake in shares of Juno Therapeutics by 878.7% in the fourth quarter. California Public Employees Retirement System now owns 105,700 shares of the biopharmaceutical company’s stock worth $4,648,000 after buying an additional 94,900 shares during the period. ProShare Advisors LLC purchased a new stake in shares of Juno Therapeutics during the fourth quarter worth about $3,674,000. Swiss National Bank purchased a new stake in shares of Juno Therapeutics during the fourth quarter worth about $2,603,000. Finally, Stevens Capital Management LP purchased a new stake in shares of Juno Therapeutics during the fourth quarter worth about $2,315,000.

Juno Therapeutics, Inc (Juno) is a biopharmaceutical company. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells. Juno’s product candidates, JCAR015, JCAR017 and JCAR014, utilize CAR technology to target CD19, a protein expressed on the surface of various B cell leukemias and lymphomas.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.